Fate Therapeutics, Inc.
Fate Therapeutics, Inc. (Nasdaq: FATE) is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies for cancer and autoimmune diseases. Its proprietary induced pluripotent stem cell (iPSC) platform engineers renewable cell lines and differentiates them into uniform, multiplexed… From the company’s description.
Over the twelve months to Sep 30, 2026, Fate Therapeutics, Inc. reported revenue of $4.75M, down 33.4% from a year earlier, and a net loss of $124.43M. Operations used $105.46M in cash. In fiscal 2025, it reported revenue of $6.65M, down 51.2% from fiscal 2024, and a net loss of $136.31M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Fate Therapeutics, Inc. does
In the company’s own words
Fate Therapeutics, Inc. (Nasdaq: FATE) is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies for cancer and autoimmune diseases. Its proprietary induced pluripotent stem cell (iPSC) platform engineers renewable cell lines and differentiates them into uniform, multiplexed T-cell and natural killer cell product candidates designed for on-demand use. The pipeline includes CD19-targeted CAR T-cell candidate FT819, under clinical investigation for systemic lupus erythematosus and other autoimmune diseases, and CAR T-cell candidate FT825 for solid tumors, developed with Ono Pharmaceutical; other programs include FT522, FT836 and FT839. The company also develops synthetic controls intended to enhance cell function and potentially reduce the need for conditioning chemotherapy. Fate operates a 40,000-plus-square-foot GMP manufacturing facility supporting clinical development and potential initial commercialization. In fiscal 2025, it reported no product sales and recorded $7.7 million in collaboration revenue. Its business is organized as one operating and reportable segment. Its website is https://fatetherapeutics.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1434316
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Fate Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Fate Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Fate Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Fate Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Fate Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”